Literature DB >> 22956185

What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients?

Fahad Waqar1, Stephanie H Dunlap, Myron C Gerson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956185     DOI: 10.1007/s12350-012-9612-z

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  56 in total

1.  Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine.

Authors:  Myron C Gerson; Laura L Craft; Nancy McGuire; Damodhar P Suresh; William T Abraham; Lynne E Wagoner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  ACE inhibitor dosage at the time of listing predicts survival.

Authors:  R Berger; G Kuchling; B Frey; I Kozanly; R Pacher; B Stanek
Journal:  J Heart Lung Transplant       Date:  2000-02       Impact factor: 10.247

3.  Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol.

Authors:  Shu Kasama; Takuji Toyama; Takashi Hatori; Hiroyuki Sumino; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  Eur Heart J       Date:  2007-04-04       Impact factor: 29.983

4.  Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group.

Authors:  J N Nanas; G Alexopoulos; M I Anastasiou-Nana; K Karidis; A Tirologos; S Zobolos; V Pirgakis; L Anthopoulos; D Sideris; S F Stamatelopoulos; S D Moulopoulos
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

5.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

Authors:  F Waagstein; K Caidahl; I Wallentin; C H Bergh; A Hjalmarson
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

6.  Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program.

Authors:  Peter A Meredith; Jan Ostergren; Inder Anand; Margareta Puu; Scott D Solomon; Eric L Michelson; Bertil Olofsson; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2008-12-09       Impact factor: 24.094

7.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

8.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.

Authors: 
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

9.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy.

Authors:  F Peters-Klimm; T Müller-Tasch; D Schellberg; A Remppis; A Barth; N Holzapfel; J Jünger; W Herzog; J Szecsenyi
Journal:  Clin Res Cardiol       Date:  2007-11-28       Impact factor: 5.460

View more
  2 in total

1.  Cardiac sympathetic imaging in the diagnosis of cardiac autonomic neuropathy in pre-diabetes.

Authors:  Fahad Waqar; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2015-03-05       Impact factor: 5.952

Review 2.  Cardiac autonomic imaging with SPECT tracers.

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2013-02       Impact factor: 5.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.